Benefits of candesartan on arterial and renal damage of non-diabetic hypertensive patients treated with calcium channel blockers

Atsuhiro Ichihara, Yuki Kaneshiro, Tomoko Takemitsu, Mariyo Sakoda, Hiroshi Itoh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background/Aim: Although long-term, intensive blood pressure (BP) control with calcium channel blockers (CCBs) reduced arterial stiffness and renal damage of hypertensive patients, combination therapy with antihypertensive drugs is frequently needed to maintain the intensive BP control. The present study was conducted to examine add-on benefits of candesartan therapy on hypertensive patients treated with CCBs for at least 12 months. Methods: Pulse wave velocity (PWV), urinary albumin excretion (UAE), intima-media thickness (IMT) of the carotid arteries, and 24-hour ambulatory BP were determined in 50 non-diabetic hypertensive patients treated with CCBs before and 12 months after the start of therapy with candesartan or placebo. Results: Candesartan significantly decreased clinic BP and tended to decrease ambulatory BP, but the decreases were similar to those in the placebo group except nocturnal BP decrease, which was significantly enhanced by candesartan. Add-on candesartan significantly decreased PWV and UAE compared to placebo, but IMT was unchanged with candesartan or placebo. The decrease in clinic BP or nocturnal BP decrease did not contribute to the improvement of PWV or UAE. Conclusion: Add-on candesartan functionally improved the stiffened arteries of hypertensive patients treated with CCBs by the end of 12 months of treatment independently of its effects on BPs.

Original languageEnglish
Pages (from-to)462-468
Number of pages7
JournalAmerican Journal of Nephrology
Volume26
Issue number5
DOIs
Publication statusPublished - 2006 Dec

Fingerprint

Calcium Channel Blockers
Blood Pressure
Kidney
Pulse Wave Analysis
Placebos
Albumins
Vascular Stiffness
candesartan
Therapeutics
Carotid Arteries
Antihypertensive Agents
Arteries

Keywords

  • Ambulatory blood pressure
  • Candesartan, pleiotropic effects
  • Intima-media thickness
  • Microalbuminuria
  • Pulse wave velocity

ASJC Scopus subject areas

  • Nephrology

Cite this

Benefits of candesartan on arterial and renal damage of non-diabetic hypertensive patients treated with calcium channel blockers. / Ichihara, Atsuhiro; Kaneshiro, Yuki; Takemitsu, Tomoko; Sakoda, Mariyo; Itoh, Hiroshi.

In: American Journal of Nephrology, Vol. 26, No. 5, 12.2006, p. 462-468.

Research output: Contribution to journalArticle

Ichihara, Atsuhiro ; Kaneshiro, Yuki ; Takemitsu, Tomoko ; Sakoda, Mariyo ; Itoh, Hiroshi. / Benefits of candesartan on arterial and renal damage of non-diabetic hypertensive patients treated with calcium channel blockers. In: American Journal of Nephrology. 2006 ; Vol. 26, No. 5. pp. 462-468.
@article{3e1ebf3e2d19448ca86d292991ae5fc4,
title = "Benefits of candesartan on arterial and renal damage of non-diabetic hypertensive patients treated with calcium channel blockers",
abstract = "Background/Aim: Although long-term, intensive blood pressure (BP) control with calcium channel blockers (CCBs) reduced arterial stiffness and renal damage of hypertensive patients, combination therapy with antihypertensive drugs is frequently needed to maintain the intensive BP control. The present study was conducted to examine add-on benefits of candesartan therapy on hypertensive patients treated with CCBs for at least 12 months. Methods: Pulse wave velocity (PWV), urinary albumin excretion (UAE), intima-media thickness (IMT) of the carotid arteries, and 24-hour ambulatory BP were determined in 50 non-diabetic hypertensive patients treated with CCBs before and 12 months after the start of therapy with candesartan or placebo. Results: Candesartan significantly decreased clinic BP and tended to decrease ambulatory BP, but the decreases were similar to those in the placebo group except nocturnal BP decrease, which was significantly enhanced by candesartan. Add-on candesartan significantly decreased PWV and UAE compared to placebo, but IMT was unchanged with candesartan or placebo. The decrease in clinic BP or nocturnal BP decrease did not contribute to the improvement of PWV or UAE. Conclusion: Add-on candesartan functionally improved the stiffened arteries of hypertensive patients treated with CCBs by the end of 12 months of treatment independently of its effects on BPs.",
keywords = "Ambulatory blood pressure, Candesartan, pleiotropic effects, Intima-media thickness, Microalbuminuria, Pulse wave velocity",
author = "Atsuhiro Ichihara and Yuki Kaneshiro and Tomoko Takemitsu and Mariyo Sakoda and Hiroshi Itoh",
year = "2006",
month = "12",
doi = "10.1159/000096581",
language = "English",
volume = "26",
pages = "462--468",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Benefits of candesartan on arterial and renal damage of non-diabetic hypertensive patients treated with calcium channel blockers

AU - Ichihara, Atsuhiro

AU - Kaneshiro, Yuki

AU - Takemitsu, Tomoko

AU - Sakoda, Mariyo

AU - Itoh, Hiroshi

PY - 2006/12

Y1 - 2006/12

N2 - Background/Aim: Although long-term, intensive blood pressure (BP) control with calcium channel blockers (CCBs) reduced arterial stiffness and renal damage of hypertensive patients, combination therapy with antihypertensive drugs is frequently needed to maintain the intensive BP control. The present study was conducted to examine add-on benefits of candesartan therapy on hypertensive patients treated with CCBs for at least 12 months. Methods: Pulse wave velocity (PWV), urinary albumin excretion (UAE), intima-media thickness (IMT) of the carotid arteries, and 24-hour ambulatory BP were determined in 50 non-diabetic hypertensive patients treated with CCBs before and 12 months after the start of therapy with candesartan or placebo. Results: Candesartan significantly decreased clinic BP and tended to decrease ambulatory BP, but the decreases were similar to those in the placebo group except nocturnal BP decrease, which was significantly enhanced by candesartan. Add-on candesartan significantly decreased PWV and UAE compared to placebo, but IMT was unchanged with candesartan or placebo. The decrease in clinic BP or nocturnal BP decrease did not contribute to the improvement of PWV or UAE. Conclusion: Add-on candesartan functionally improved the stiffened arteries of hypertensive patients treated with CCBs by the end of 12 months of treatment independently of its effects on BPs.

AB - Background/Aim: Although long-term, intensive blood pressure (BP) control with calcium channel blockers (CCBs) reduced arterial stiffness and renal damage of hypertensive patients, combination therapy with antihypertensive drugs is frequently needed to maintain the intensive BP control. The present study was conducted to examine add-on benefits of candesartan therapy on hypertensive patients treated with CCBs for at least 12 months. Methods: Pulse wave velocity (PWV), urinary albumin excretion (UAE), intima-media thickness (IMT) of the carotid arteries, and 24-hour ambulatory BP were determined in 50 non-diabetic hypertensive patients treated with CCBs before and 12 months after the start of therapy with candesartan or placebo. Results: Candesartan significantly decreased clinic BP and tended to decrease ambulatory BP, but the decreases were similar to those in the placebo group except nocturnal BP decrease, which was significantly enhanced by candesartan. Add-on candesartan significantly decreased PWV and UAE compared to placebo, but IMT was unchanged with candesartan or placebo. The decrease in clinic BP or nocturnal BP decrease did not contribute to the improvement of PWV or UAE. Conclusion: Add-on candesartan functionally improved the stiffened arteries of hypertensive patients treated with CCBs by the end of 12 months of treatment independently of its effects on BPs.

KW - Ambulatory blood pressure

KW - Candesartan, pleiotropic effects

KW - Intima-media thickness

KW - Microalbuminuria

KW - Pulse wave velocity

UR - http://www.scopus.com/inward/record.url?scp=33845772832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845772832&partnerID=8YFLogxK

U2 - 10.1159/000096581

DO - 10.1159/000096581

M3 - Article

VL - 26

SP - 462

EP - 468

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 5

ER -